Bermele (LON:BERM) is a standard list shell seeking to buy a pharma or biotechnology business. The focus is one or more businesses which have their own intellectual property.
The areas that Bermele is assessing include diabetes, cancer and mental health. It is also looking at personalised medicine. Management will decide on which of these areas to progress when it finds its first acquisition.
The shares in the placing are 50% of the total number in issue. The other shares were issued at 0.1p each, which means that the pro forma NAV is 0.45p a share. The mid-price at the close of the firs...
